
Soviet-era spacecraft is set to plunge to Earth a half-century after its failed launch to Venus
It's too early to know where the half-ton mass of metal might come down or how much of it will survive reentry, according to space debris-tracking experts.
Dutch scientist Marco Langbroek predicts the failed spacecraft will reenter around May 10. He estimates it will come crashing in at 150 mph (242 kph), if it remains intact.
'While not without risk, we should not be too worried,' Langbroek said in an email.
The object is relatively small and, even if it doesn't break apart, 'the risk is similar to that of a random meteorite fall , several of which happen each year. You run a bigger risk of getting hit by lightning in your lifetime,' he said.
The chance of the spacecraft actually hitting someone or something is small, he added. 'But it cannot be completely excluded.'
The Soviet Union launched the spacecraft known as Kosmos 482 in 1972, one of a series of Venus missions. But it never made it out of Earth orbit because of a rocket malfunction.
Most of it came tumbling down within a decade. But Langbroek and others believe the landing capsule itself — a spherical object about 3 feet (1 meter) in diameter — has been circling the world in a highly elliptical orbit for the past 53 years, gradually dropping in altitude.
It's quite possible that the 1,000-pound-plus (nearly 500-kilogram) spacecraft will survive reentry. It was built to withstand a descent through the carbon dioxide-thick atmosphere of Venus, said Langbroek of Delft University of Technology in the Netherlands.
Experts doubt the parachute system would work after so many years. The heat shield may also be compromised after so long in orbit.
It would be better if the heat shield fails, which would cause the spacecraft to burn up during its dive through the atmosphere, the Harvard-Smithsonian Center for Astrophysics' Jonathan McDowell said in an email. But if the heat shield holds, 'it'll reenter intact and you have a half-ton metal object falling from the sky.'
The spacecraft could reenter anywhere between 51.7 degrees north and south latitude, or as far north as London and Edmonton in Alberta, Canada, almost all the way down to South America's Cape Horn. But since most of the planet is water, 'chances are good it will indeed end up in some ocean,' Langbroek said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
2 days ago
- New York Post
New tool reveals how fast you're aging — and predicts dementia years before a diagnosis
Getting older is inevitable — but illness doesn't have to be. Scientists have developed a groundbreaking tool that can measure how fast a person is aging and predict their future risk of chronic diseases like dementia using a single brain MRI scan. Researchers say this early warning could give people the chance to make lifestyle changes while they're still young and healthy enough to potentially slow or even prevent health problems down the line. Advertisement 4 The tool can predict the rate a person is aging biologically using a single MRI scan. ihorvsn – The technology is the brainchild of scientists at Duke, Harvard and New Zealand's University of Otago, who used data from the Dunedin Study — a decades-long health project tracking over 1,000 New Zealanders born in the early '70s. Since birth, participants have been poked, scanned and tested regularly. Researchers have followed everything from their blood pressure and cholesterol to lung and kidney function to map how their bodies have changed over time. Advertisement From that mountain of data, the team crunched the numbers to see how fast each person was aging biologically — not based on their birthdate, but on the physical wear and tear their body had endured. Then they trained the tool, called DunedinPACE-NI, to predict those biological ages using just a single MRI scan of the brain that was taken when participants were 45 years old. Next, they put the tool to the test, using it to analyze brain scans from people across the US, UK, Canada and Latin America. 4 The tool relies on MRI scans of the brain to gauge the pace of aging. Ethan Whitman, Duke University Advertisement Across the board, they found that people with higher aging scores performed worse on cognitive tests and showed faster shrinkage in the hippocampus, the part of the brain crucial for memory and learning. In one analysis, those who the tool deemed to be aging fastest faced a 60% higher risk of developing dementia compared to people with lower scores. They also started to have memory and thinking problems sooner. When the team first saw the results, 'our jaws just dropped to the floor,' Ahmad Hariri, a Duke professor of psychology and neuroscience, said in a statement. Advertisement 'What's really cool about this is that we've captured how fast people are aging using data collected in midlife,' he noted. 'It's helping us predict diagnosis of dementia among people who are much older.' Brain decline wasn't the only red flag the tool picked up. People with higher DunedinPACE-NI scores were also more likely to suffer from age-related frailty, heart attacks, strokes, lung disease and other chronic illnesses. 4 Dementia affects about 1 in 10 Americans over the age of 65. LIGHTFIELD STUDIOS – Even more striking, they were 40% more likely to die within the next several years than their slower-aging peers. Notably, the tool's accuracy held up across race, income and geographic location. 'It seems to be capturing something that is reflected in all brains,' Hariri said. A ticking clock Advertisement The new tool arrives as people are living longer than ever. By 2050, nearly a quarter of the global population will be over 65 — twice as many seniors as today, according to the World Health Organization. A longer life sometimes comes with a catch. 'More people are unfortunately going to experience chronic age-related diseases, including dementia,' Hariri said. 4 The tool could also help flag the risk of other age-related diseases, like stroke and heart attack. Pixel-Shot – Advertisement Studies predict 152.8 million people worldwide will be living with dementia in 25 years — up from 57.4 million cases in 2019. Despite this sharp rise, effective treatments for Alzheimer's and other dementias remain elusive. Most drugs on the market can help manage symptoms, but fail to stop or reverse the disease. One reason existing treatments haven't worked, Hariri theorized, is that they often start too late — after the disease has already done too much damage. Advertisement 'Drugs can't resurrect a dying brain,' he said. But the new tool could change that by identifying people at risk of Alzheimer's earlier, allowing for interventions before extensive brain damage occurs. Beyond just predicting dementia risk, the new clock will help scientists figure out why people with certain risk factors — like poor sleep or mental health issues — age differently, said Ethan Whitman, first author on the study and a clinical psychology PhD candidate at Duke. However, he noted that more work is needed to turn DunedinPACE-NI into a tool that everyday healthcare providers can use. Advertisement In the meantime, the team hopes the tool will help researchers with access to brain MRI data to measure aging in a way that algorithms based on other biomarkers, such as blood tests, can't. 'We really think of it as hopefully being a key new tool in forecasting and predicting risk for diseases, especially Alzheimer's and related dementias, and also perhaps gaining a better foothold on progression of disease,' Hariri said.


Fast Company
2 days ago
- Fast Company
The health research Trump really cut when he joked about defunding trans mice
In a high-profile attack on LGBTQ science research this spring, President Donald Trump decried supposedly wasteful research like $8 million for 'making mice transgender.' Trump played the mice remark for laughs during a joint address to Congress on March 4. But the $8 million in funding was not a joking matter; the federal grants supported six research efforts funded by the National Institutes of Health that focused on HIV, asthma, infertility, breast cancer, and other pressing concerns. These studies are among countless medical and public health research initiatives, many benefiting LGBTQ patients, that were targeted by the administration this year—NIH terminated or delayed more than 2,400 grants, according to an analysis by The New York Times. And while it's not known how many of the NIH cuts were LGBTQ-focused or LGBTQ-inclusive, it's undisputed that they were driven by the fervor against diversity, equity, and inclusion policies, or DEI. Not all the administration's cuts to research budgets are aimed at individual scientists; some target an entire university, such as at Harvard, and others take aim at once-celebrated health missions, such as ending support for the development of an HIV vaccine. Even as universities and scientists are pushing back in the courts with some notable success, medical research is in disarray. The termination of LGBTQ-benefiting medical research comes at a time when more people are identifying as LGBTQ than ever before. Research shows LGBTQ youth are at higher risk of poor mental health such as suicidal thoughts, experiences of violence, and sexually transmitted infections. LGBTQ communities would be the prime beneficiaries of the studies involving so-called transgender mice, but the findings also had the potential to improve the health of cisgender women, according to scientists involved in the work. 'It's funny to imagine a mouse being canceled for being trans. That's not at all what's happening,' said Dane Samilo of Out to Innovate, a society of LGBTQ students and professionals in science, technology, engineering, and mathematics. 'We're not funding things that are frivolous. This is science that is relevant and rigorous and has potential implications.' What Does It Mean to 'Make Mice Transgender'? The $8 million in grants from the NIH cited by Trump helped fund six research efforts that were focused on the role of hormones and hormone therapies in disease treatment and prevention. One of the studies listed as 'making mice transgender' was led by Patricia Silveyra, who is a lung disease researcher, a professor, and chair of the environmental and occupational health department at Indiana University. Her focus is not transgender health, though her findings could possibly benefit trans women, among a larger pool of patients. She is studying how asthma is affected by female hormones, which have been linked to more severe symptoms. To do this, she's using mice that were genetically modified to share opposite sex traits. She said her findings could pave the way for a new drug for asthmatic women dealing with hormonal changes as a result of pregnancy, giving birth, taking oral contraception, or while transitioning from male to female. An estimated 10% of the U.S. adult female population suffers from asthma. 'Part of what we're trying to understand is how the hormones regulate the process that leads to asthma so that we can treat it directly,' said Silveyra, whose team has published seven papers from her multiyear research on the subject. Silveyra's grant that Trump cited did not, in the end, get canceled. She received a one-year, no-cost extension through next June, a status that allows scientists to continue their grant research but without any new funding. HIV Erasure Another project called out by the administration enabled scientists to treat mice with opposite-sex hormones to study how gender-affirming hormone therapy affects the immune system's response to HIV vaccines, especially in transgender women, who are at a higher risk for HIV and other sexually transmitted infections. The goal was to understand the influence of sex hormones on immunological health, and inform more effective vaccine designs. Worldwide, transgender people are 13 times more likely to be HIV-positive than the general population. Findings from the study could have benefited not only the transgender population but also cisgender women, who are more prone to autoimmune disorders and adverse effects to vaccines, and to cisgender men, who have a higher mortality rate when it comes to certain diseases such as SARS and COVID-19, according to Aria Arus-Altuz of the Duke Human Vaccine Institute. Arus-Altuz said the end of HIV vaccine research 'hurts deeply,' acknowledging that while there are treatments that extend patients' lives, 'there are communities around the world where lifelong treatments are neither affordable nor accessible. . . . A preventative vaccine is key to ending this epidemic once and for all.' Beyond Mice Numerous other LGBTQ-inclusive medical studies, not involving mice, have been targeted in the so-called war on woke and waste in science. On March 7, Brooke Rollins, U.S. Department of Agriculture secretary, announced the cancellation of a $600,000 grant to study what she called 'menstrual cycles in transgender men.' But the researcher actually sought to study the toxic synthetics in feminine hygiene products and their possible replacement by natural fibers grown in Louisiana. Trans men who still get a period were mentioned once in the NIH summary, which otherwise focused on women of menstruating age. Studying and Caring for LGBTQ Communities The budget axe also fell on public health research, including a study of 900 LGBTQ people of color to examine how race- and gender-based stigma affect HIV risk and participation in HIV prevention initiatives. This study was to be led by researcher Sean Arayasirikul, a medical sociologist and an associate professor at the University of California, Irvine, who had two other studies canceled and one delayed by NIH earlier this year. The other grants would have supported training of public health students and professionals to conduct research into sexual and gender minorities—which Arayasirikul called a highly under-researched group. 'The grants focused on educating the next generation of the public health workforce to study HIV but also serve and care for LGBTQ people,' said Arayasirikul, who goes by they/them. 'The impacts of terminating those grants cut very deep.' Arayasirikul has joined a group of scientists who on May 20 sued NIH in the U.S. District Court in Maryland over the termination of grants affecting LGBTQ people. That case is pending. A recent court ruling offers some hopeful signs for scientists. On June 16, U.S. District Court Judge William G. Young of Massachusetts ordered the NIH to restore approximately 800 of the more than 2,400 grants it had revoked or delayed. He called the cuts discriminatory on the basis of race and against the LGBTQ community. Still, scientists remain wary. The ruling applies only to grants named in the lawsuits and in the 16 states where attorneys general brought suit. The U.S. Department of Health and Human Services, which oversees NIH, 'is exploring all legal options, including filing an appeal and moving to stay the order,' according to Andrew Nixon, HHS director of communications. In addition, the fate of funding beyond next year casts a long shadow over the future of scientific research. Meanwhile, those researchers who are LGBTQ feel doubly targeted: both as scientists and as members of a community that has been in the administration's crosshairs. 'They are killing two birds with one stone,' said Dane Samilo of Out to Innovate. 'Trans people's rights and protections are on the docket. But then so is funding for science in general.'
Yahoo
3 days ago
- Yahoo
AstraZeneca (AZN) Announces Strategic Research Collaboration with CSPC Pharmaceuticals
AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City. The research collaboration aims to discover and develop novel oral candidates with the hopes of treating diseases across multiple indications. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. Under the agreement, the two companies will discover and develop pre-clinical candidates for various targets related to the treatment of diseases across chronic indications. This includes a pre-clinical small molecule oral therapy for immunological diseases. CSPC would conduct the research in Shijiazhuang City, utilizing its AI-driven, dual-engine efficient drug discovery platform. The collaboration is expected to expand AstraZeneca PLC's (NASDAQ:AZN) presence in China following the announcement of a $2.5 billion investment to develop a new global strategic R&D center in Beijing earlier in the year. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.